Skip to main content

Peer Review reports

From: A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer

Original Submission
24 Jun 2024 Submitted Original manuscript
11 Jul 2024 Reviewed Reviewer Report
30 Jan 2025 Reviewed Reviewer Report
25 Feb 2025 Author responded Author comments - Narikazu Boku
26 Feb 2025 Reviewed Reviewer Report
4 Mar 2025 Reviewed Reviewer Report
6 Mar 2025 Author responded Author comments - Narikazu Boku
Resubmission - Version 2
25 Feb 2025 Submitted Manuscript version 2
14 Mar 2025 Reviewed Reviewer Report
23 Mar 2025 Author responded Author comments - Narikazu Boku
Resubmission - Version 3
23 Mar 2025 Submitted Manuscript version 3
24 Mar 2025 Author responded Author comments - Narikazu Boku
Resubmission - Version 4
24 Mar 2025 Submitted Manuscript version 4
3 Apr 2025 Reviewed Reviewer Report
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
3 Apr 2025 Editorially accepted
12 Apr 2025 Article published 10.1186/s12885-025-14084-1

You can find further information about peer review here.

Back to article page